A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).

[1]  M. Stockler,et al.  Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. , 2017, The Lancet. Oncology.

[2]  P. Stricker,et al.  Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET , 2017, Journal of Nuclear Medicine.

[3]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[4]  H. Kauczor,et al.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  C. Catton,et al.  Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Low,et al.  Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.

[8]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[9]  W. J. Morris,et al.  Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity. , 2015, Brachytherapy.

[10]  S. Tyldesley,et al.  Underutilization of local salvage therapy after radiation therapy for prostate cancer. , 2014, Urologic oncology.

[11]  A. Aprikian,et al.  Drug costs in the management of metastatic castration-resistant prostate cancer in Canada , 2014, BMC Health Services Research.

[12]  Daniel A Hamstra,et al.  Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. , 2013, International journal of radiation oncology, biology, physics.

[13]  Fred Saad,et al.  Intermittent androgen suppression for rising PSA level after radiotherapy. , 2012, The New England journal of medicine.

[14]  P. Carroll,et al.  Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. , 2012, International journal of radiation oncology, biology, physics.

[15]  John T. Wei,et al.  Prediction of erectile function following treatment for prostate cancer. , 2011, JAMA.

[16]  P. Maingon,et al.  70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. , 2011, International journal of radiation oncology, biology, physics.

[17]  F. Vicini,et al.  Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[18]  H. G. van der Poel,et al.  Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. , 2010, Brachytherapy.

[19]  Kyounghwa Bae,et al.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Unger,et al.  Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[21]  Ronald C. Chen,et al.  Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. , 2009, Brachytherapy.

[22]  I. Hsu,et al.  Salvage permanent perineal radioactive‐seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy , 2009, BJU international.

[23]  G. Viani,et al.  High Dose Rate and External Beam Radiotherapy in Locally Advanced Prostate Cancer , 2009, American journal of clinical oncology.

[24]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[25]  Victor E Reuter,et al.  Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. , 2008, The Journal of urology.

[26]  A. D'Amico,et al.  Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate‐specific antigen failure , 2007, Cancer.

[27]  H. Hricak,et al.  Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. , 2007, International journal of radiation oncology, biology, physics.

[28]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[29]  B. Davis,et al.  Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. , 2006, The Journal of urology.

[30]  R. Stock,et al.  Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. , 2006, International journal of radiation oncology, biology, physics.

[31]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Bristow,et al.  A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  A. D'Amico,et al.  Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. , 2005, The Journal of urology.

[35]  A. Markoe,et al.  Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. , 2004, International journal of radiation oncology, biology, physics.

[36]  A. Zietman,et al.  Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Beyer,et al.  Permanent brachytherapy as salvage treatment for recurrent prostate cancer. , 1999, Urology.

[38]  Grado Gl.  Benefits of brachytherapy as salvage treatment for radiorecurrent localized prostate cancer. , 1999 .

[39]  A. Pollack,et al.  Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  C B Begg,et al.  The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. , 1991, International journal of radiation oncology, biology, physics.

[41]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[42]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[43]  A. Hanlon,et al.  Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[44]  G. Grado.  Benefits of brachytherapy as salvage treatment for radiorecurrent localized prostate cancer. , 1999, Urology.

[45]  G. Perry,et al.  Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma , 1997, Cancer.